摘要
目的:探讨microRNA-6886(miR-6886)和microRNA-6819(miR-6819)在乳腺肿块良恶性患者血浆外泌体中的表达水平及鉴别诊断价值。方法:分别选取41例和18例经病理确诊为乳腺恶性肿块和乳腺良性肿块的患者。通过Exo QuickTM试剂盒分离两组患者血浆外泌体,实时荧光定量PCR检测血浆外泌体中miR-6886、miR-6819和miR-7110的相对表达水平。采用受试者工作特征曲线(ROC)分析单个miRNA或多个miRNA联合在乳腺良恶性肿块鉴别诊断中的价值。各组间比较采用非参数秩和检验进行分析。结果:乳腺恶性肿块组中血浆外泌体miR-6886和miR-6819的表达水平明显低于乳腺良性肿块组,差异具有统计学意义(miR-6886,Z=-2.321,P=0.020;miR-6819,Z=-2.321,P=0.020)。miR-7110的表达水平在两组间没有统计学差异。单个miRNA检测时,miR-6886的AUCROC=0.691,灵敏度和特异度分别为65.8%和72.2%;miR-6819的AUCROC=0.691,灵敏度和特异度分别为73.1%和66.6%;miR-6886和miR-6819联合检测时,AUCROC=0.806,灵敏度和特异度分别为80.5%和77.8%,与单独miR-6886和miR-6819检测相比,AUC差异均有统计学意义(miR-6886,Z=4.082,P<0.001;miR-6819,Z=2.182,P=0.029)。结论:血浆外泌体miR-6886+miR-6819联合检测,有望成为良好的乳腺良恶性肿瘤鉴别的血清学标志物。
Objective:To explore the express levels and diagnostic values of microRNA-6886(miR-6886)and microRNA-6819(miR-6819)in plasma exosomes of patients with the benign and malignant breast masses.Methods:The study enrolled 41 patients and 18 ones respectively with pathological diagnosis of breast malignant tumor and benign breast diseases patients.Separating the plasma exosomes of the two-group patients and detecting the relative expression level of the miR-6886,miR-6819 and miR-7110 with real-time fluorescent quantitative PCR.The value of a single miRNA or joint miRNAs in differential diagnosis of the benign and malignant breast masses was analyzed by the receiver-operating characteristic curve(ROC).Groups were compared by nonparametric rank and inspection.Results:The express levels of miR-6886 and miR-6819 of plasma exosomes in the malignant breast tumor group were,significantly lower than those in the benign breast tumor group,which showed statistical difference(miR-6886,Z=-2.321,P=0.020;miR-6819,Z=-2.321,P=0.020).The expression levels of miR-7110 showed no statistical difference between the two groups.When miR-6886 and miR-6819 was tested separately,the AUCROC of miR-6886 was 0.691,and the sensitivity and specificity were 65.8%and 72.2%;the AUCROC of miR-6819 was 0.691,the sensitivity and specificity were 73.1%and 66.6%.While combining miR-6886and miR-6819,the AUCROC=0.806,the sensitivity and specificity were 80.5%and 77.8%.Comparing with the separated testing,the AUC differences of combining tests were statistically significant(miR-6886,Z=4.082,P<0.001;miR-6819,Z=2.182,P=0.029).Conclusion:The combined detection of plasma exosome,miR-6886 and miR-6819,is expected to be a good serological marker for the differentiation of benign and malignant breast tumors.
作者
周永刚
李者龙
邢长洋
杨泽利
金京兰
袁丽君
ZHOU Yong-gang;LI Zhe-long;XING Chang-yang;YANG Ze-li;JIN Jing-lan;YUAN Li-jun(Department of Ultrasound Diagnostics,Tangdu Hospital,Fourth Military Medical University,Xi'an,Shaanxi,710038,China)
出处
《现代生物医学进展》
CAS
2021年第20期3898-3902,3926,共6页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81871357)
陕西省重点研发计划项目(2021SF-007)。
